qqqq has a point harvett - we should hold Novogen to the same...

qqqq has a point harvett - we should hold Novogen to the same scrutiny we do with any other stock. Having said we can as always only speculate which is what qqqq is doing and in reply aren't we also doing the same?

One thing is known and that is JG has the company sticking to timelines - that being said we should be reasonably confident we'll know a hell of a lot more in the next few months around GDC-0084, Cantrixil & whatever else as its not likely going to simply be an announcement that GDC-0084 is going into trial without a blueprint of funding going forward.

All in all qqqq knows as much as us - and as always we'll know when we know - lets see what happens qqqq - I'm confident we'll have an answer in the coming months (Before end of 2017)...